title: Combined treatment with GH and anastrozole in a pubertal boy with Cushing's disease and postsurgical GH deficiency.
abstract: Growth failure is a characteristic manifestation of pediatric Cushing's disease. Catch-up growth is usually incomplete after cure of the disease, and final height is often compromised. Possible mechanisms for this phenomenon include postoperative persistence of GH hyposecretion and absence of retardation of bone maturation in spite of GH deficiency. This report describes the outcome in the case of a boy with Cushing's disease for whom GH replacement therapy was combined with anastrozole, an aromatase inhibitor, in order to delay skeletal maturation and extend the available time for linear growth. The case of a 14 years 4-months-old pubertal male (Tanner stage III) with GH deficiency after successful surgical treatment of Cushing's disease is presented. His height was 147.2 cm (-2.34 SDS), and his midparental target height 171.2 cm (-0.95 SDS). Bone age was 13.5 years and predicted adult height 163.2 cm (-2.2 SDS). Combined treatment was administered for 2.5 years. GH was maintained up to age 18 years. Anastrozole induced a substantial deceleration of bone age. Near-final height at 18 years was 169.5 cm (-1.07 SDS). Puberty progressed normally. Compared with population reference data, bone mineral density before GH plus anastrozole treatment was -4.07 SDS in the lumbar spine and -1.85 SDS in the femoral neck. These measures increased to -1.95 and -0.89 SDSs respectively, at 18 years, when GH was discontinued. Combined treatment with GH and aromatase inhibitors could be a therapeutic alternative to improve the stature of pubertal boys with Cushing's disease and postsurgical GH deficiency.
authors.affiliation: Section of Endocrinology and Nutrition, Las Palmas University, Hospital Universitario Insular, Avda. Marítima del Sur s/n, Las Palmas de Gran Canaria, Spain. mborcor@yahoo.es
authors.forename: Mauro
authors.initials: M
authors.lastname: Boronat
authors.forename: Dunia
authors.initials: D
authors.lastname: Marrero
authors.forename: Yaiza
authors.initials: Y
authors.lastname: López-Plasencia
authors.forename: Yeray
authors.initials: Y
authors.lastname: Nóvoa
authors.forename: Yaiza
authors.initials: Y
authors.lastname: García-Delgado
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Nóvoa
mesh_terms: D000293:Adolescent; D000077384:Anastrozole; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001827:Body Height / Q000187:drug effects; D004359:Drug Therapy, Combination; D006130:Growth Disorders / Q000188:drug therapy* / Q000209:etiology; D020249:Hormone Replacement Therapy; D019382:Human Growth Hormone / Q000008:administration & dosage* / Q000172:deficiency*; D006801:Humans; D008297:Male; D009570:Nitriles / Q000627:therapeutic use*; D047748:Pituitary ACTH Hypersecretion / Q000601:surgery*; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D019382:Human Growth Hormone; D000077384:Anastrozole